Drug
Mirvetuximab soravtansine clinical trials
Also written IMGN853 and Elahere.
- studies test it
- 27
- open now
- 9
- in phase 3
- 5
- first study started
- 2012
Keep track of what changes. Save the mirvetuximab soravtansine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Combined with it in one product
- MIRV
- 1
Studies by the year they started
27 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 17
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 11
AbbVie (7) · ImmunoGen, Inc. (4) · Takeda (1) · Dana-Farber Cancer Institute (1) · AGO Research GmbH (1) · City of Hope Medical Center (1) · Ohio State University Comprehensive Cancer Center (1) · Pfizer (1)
Often tested with
Tested in the same studies.
Bevacizumab (4) · Carboplatin (3) · Pembrolizumab (2) · Liposomal doxorubicin (2) · Doxorubicin (2) · Gemcitabine (1) · Rucaparib (1) · Influenza Vaccines (1)
Studies
Open first, then newest update. How each study uses mirvetuximab soravtansine is read from its arms, and is right about nine times in ten.
Testing it · 27
- A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.RecruitingPhase 2AbbVieNCT06890338Written as Mirvetuximab Soravtansine
- A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian CancerRecruitingPhase 2AbbVieNCT07059845Written as Mirvetuximab Soravtansine
- A Study of PHST001 in Advanced Solid TumorsRecruitingPhase 1Pheast TherapeuticsNCT06840886Written as Mirvetuximab Soravtansine
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07825753Written as Mirvetuximab soravtansine (MIRV)
- Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian CancerNot yet recruitingPhase 2Peking University Third HospitalNCT07741630Written as Mirvetuximab soravtansine
- Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal CancerRecruitingPhase 2University of Alabama at BirminghamNCT04606914Written as mirvetuximab soravtansine (MIRV; IMGN853)
- An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and OlaparibRecruitingPhase 2University of Colorado, DenverNCT05887609Written as Mirvetuximab Soravtansine-gynx
- Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial CancerRecruitingPhase 2Alessandro SantinNCT03832361Written as IMGN853
- A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab SoravtansineRecruitingPhase 2AbbVieNCT06682988Written as Mirvetuximab Soravtansine
- Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast CancerCompletedPhase 1City of Hope Medical CenterNCT02996825Written as Mirvetuximab Soravtansine
- A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid TumorsActive, not recruitingPhase 1/2TakedaNCT06390995Written as TAK-853
- Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerActive, not recruitingPhase 3AbbVieNCT05445778Written as Mirvetuximab soravtansine plus Bevacizumab
- A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)Active, not recruitingPhase 2Dana-Farber Cancer InstituteNCT03835819Written as IMGN853
- Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian CancerActive, not recruitingPhase 2AGO Research GmbHNCT04274426Written as Mirvetuximab Soravtansine
- Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube CancersCompletedPhase 2AbbVieNCT05041257Written as Mirvetuximab soravtansine
- Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancerActive, not recruitingPhase 2AbbVieNCT05456685Written as Mirvetuximab soravtansine
- A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) ExpressionCompletedPhase 3AbbVieNCT04209855Written as Mirvetuximab Soravtansine
- Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedPhase 1Ohio State University Comprehensive Cancer CenterNCT03552471Written as Mirvetuximab Soravtansine
- A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionCompletedPhase 3ImmunoGen, Inc.NCT04296890Written as Mirvetuximab Soravtansine
- Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube CancerCompletedPhase 1/2ImmunoGen, Inc.NCT02606305Written as Mirvetuximab soravtansine
See all 27 studies that test mirvetuximab soravtansine →
Given in every arm · 1 — mirvetuximab soravtansine is usual care beside what is tested
As the comparator · 2 — what is tested is compared with mirvetuximab soravtansine
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerRecruitingPhase 3Eli Lilly and CompanyNCT07213804Written as MIRV
- AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian CancerRecruitingPhase 3AstraZenecaNCT07218809Written as Mirvetuximab Soravtansine (MIRV)
Codes
What other systems call mirvetuximab soravtansine · ClinicalTrials.gg INT000444
- MeSH (NLM) C000607289mirvetuximab soravtansineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 98DE7VN88DMIRVETUXIMAB SORAVTANSINEConfirmed FDA, NLM, Wikidata
- RxNorm 2621548One source FDA
- Wikidata Q115285803mirvetuximab soravtansineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C102566Mirvetuximab SoravtansineOne source FDA
- DrugBank DB12489One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000607289 | mirvetuximab soravtansine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 98DE7VN88D | MIRVETUXIMAB SORAVTANSINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2621548 | — | One source FDA |
| Wikidata | Q115285803 | mirvetuximab soravtansine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C102566 | Mirvetuximab Soravtansine | One source FDA |
| DrugBank | DB12489 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.